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Journal of Stroke and CBackground: Managing hypertension is crucial for preventing stroke recurrence.
Some stroke patients experience resistant hypertension. In our experimental stroke
model, olmesartan increased the expression of angiotensin (Ang) II converting
enzyme-2. We hypothesized that switching to olmesartan affects biomarkers and
the blood pressure (BP) in stroke patients whose BP is insufficiently controlled by
standard doses of Ang II type I receptor blockers (ARBs) other than olmesartan.
Methods:We recruited 25 patients to study our hypothesis. All had a history of stroke
or silent cerebral infarction. We switched them to olmesartan (10-40 mg per day) for
12 weeks and determined their plasma level of Ang-(1-7), peroxiredoxin, oxidized
low-density lipoprotein (oxLDL)/b-2-glycoprotein I (b2GPI) complex, adiponectin,
high mobility group box 1 (HMGB1), and tumor necrosis factor-a (TNFa) and re-
corded theirBPbeforeandafterolmesartan treatment.Results:After switching thepa-
tients to olmesartan, their plasma level of Ang-(1-7) as a vasoprotective indicator and
adiponectin regulating metabolic syndrome was increased, and peroxiredoxin and
the oxLDL/b2GPI complex indicating its antioxidative stress and its proatherogenic-
ity were lower than their baseline. This suggests that olmesartan may be more effec-
tive than other ARBs to improve these conditions. Neither HMGB1 nor TNFa
reflecting an inflammatory response was affected, suggesting that the anti-
inflammatory effects of olmesartan are similar to those of otherARBs. The recommen-
ded BP (,140/90) was obtained in 10 of the 25 patients after switching to
olmesartan. No adverse events occurred. Conclusions: Switching from other ARBs
to olmesartan may be a promising therapeutic option in patients with resistant
hypertension. Key Words: Adiponectin—angiotensin-(1-7)—hypertension—LDL/
b-2-glycoprotein I complex—olmesartan—peroxiredoxin.
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Y. TADA ET AL.1488Although managing hypertension is the most impor-
tant issue for preventing stroke recurrence, some stroke
patients manifest treatment-resistant hypertension.
Angiotensin (Ang) II type I receptor blockers (ARBs)
exert beneficial effects for the secondary prevention of
stroke.1 Ang II plays an important role in blood pressure
(BP) regulation and is involved in the development of
hypertension, stroke, cerebral aneurysms, atheroscle-
rosis, heart failure, type 2 diabetes mellitus, and renal
disease.2-5 Most actions of Ang II are mediated
through the Ang type I receptor (AT1R). Olmesartan
has been reported to show a higher level of binding
with AT1R and stronger hypotensive effects than other
ARBs.6-8
Elsewhere, we demonstrated that in ovariectomized
rats, olmesartan suppresses the incidence of cerebral an-
eurysms and exerts neuroprotective effects against cere-
bral ischemia in a BP-independent manner.3,4 We
suggested that its efficacy is associated with the
inhibition of the renin–angiotensin system and its
antioxidative and anti-inflammatory effects. We also re-
ported that olmesartan increased the mRNA level of
angiotensin-converting enzyme 2 (ACE2), a novel homo-
logue of ACE, and reduced the expression of Ang II in
ovariectomized rats.3 The expression of ACE2 in the brain
attenuates neurogenic hypertension9 and ACE2 metabo-
lizes Ang II to Ang-(1-7) which exerts antihypertensive ef-
fects and a broad range of effects in different organs and
tissues.10,11 However, whether olmesartan increases Ang-
(1-7) in humans remained unknown.
Most ARBs increase the plasma Ang II level by uncou-
pling the negative feedback on renin activity. According
to Tsutamoto et al,12 replacing candesartan with olmesar-
tan in patients with essential hypertension decreased
plasma Ang II without changing the BP or the level of
plasma aldosterone and resulted in a decrease in the
left ventricular mass index. Compared with telmisartan,
olmesartan also improved glycemic control and insulin
resistance, suggesting that in addition to its hypotensive
effects, it exerts BP-independent beneficial systemic
effects.13
We tested our hypothesis that replacing other ARBs
with olmesartan increases Ang-(1-7) and improves
inflammation-related biomarkers, oxidative stress, and
metabolic syndrome. Focusing on hypertensive stroke pa-
tients whose BP was suboptimal after at least 3-month
treatment with other ARBs, we assessed whether olme-
sartan improved the level of Ang-(1-7), inflammation
(high mobility group box 1 [HMGB1] and tumor necrosis
factor-a [TNFa]), oxidative stress (peroxiredoxin), insulin
resistance–related molecules (adiponectin), and the
oxidized low-density lipoprotein (oxLDL)/b-2-
glycoprotein I (b2GPI) complex. We also determined
whether their BP was better controlled by switching to
olmesartan.Methods
Study Population
The following were our inclusion criteria: (1) hyperten-
sion without adequate BP control (office BP$ 140/90), (2)
3 months or more of antihypertensive treatment with
standard doses of ARBs other than olmesartan (losartan,
telmisartan, valsartan, and candesartan), and (3) stroke
more than 3 months earlier or an incidental diagnosis of
silent cerebral infarction on magnetic resonance (MR) im-
ages and MR angiograms obtained for a brain health
checkup. Excluded were patients with secondary hyper-
tension, hypersensitivity to olmesartan, arrhythmia, ma-
lignant disease, serious renal dysfunction (serum
creatinine . 2 mg/dL), or chronic inflammatory disease,
and patients currently treated for congestive heart failure.
Between July 2009 and December 2012, we recruited 26
consecutive stroke patients with treatment-resistant hy-
pertension. Based on findings reported in previous
studies,14-16 we switched them from other ARBs to
comparable dose level of olmesartan. Our study
protocol was approved by the ethics committee of our
institute. Informed written consent was obtained from
all patients before switching them from the other ARBs
to olmesartan.
Study Design
Ours is a single-center, prospective, open-label study.
Hypertensive patients were switched from other ARBs to
standard doses (10-40 mg/day) of olmesartan medoxomil
(Olmetec; Daiichi-Sankyo Co., Ltd., Tokyo, Japan) for the
first 4 weeks. Antihypertensive treatments other than
ARBs used before enrollment were continued throughout
this study. Patientswhomet the BP goal of less than140/90
after 4weeks of olmesartan continued their regimen for an
additional 8 weeks. If the goal was not reached within the
first 4 weeks, the olmesartan dosewas titrated up to 40mg
per day over the next 8 weeks.
Measurement of Biomarkers of Inflammation and
Oxidative Stress
Blood samples were drawn at the inception of the study
to obtain baseline values and again at week 12. They were
centrifuged and stored at280C until analysis. The levels
of Ang-(1-7), adiponectin, peroxiredoxin, HMGB1, and
TNFa were determined using ELISA kits according to
the manufacturer’s instructions (for Ang-(1-7), USCN
Life Science Inc., Wuhan, China; for adiponectin and
TNFa, R&D Systems, Minneapolis, MN; for peroxire-
doxin, Japan Institute for the Control of Aging, Fukuroi,
Japan; and for HMGB1, Shino-Test Corp., Tokyo, Japan).
ELISA for oxLDL/b2GPI complexes17 was performed at
Okayama University of Graduate School of Medicine,
Dentistry, and Pharmaceutical Sciences.
Table 1. Clinical baseline characteristics of the patients
Male sex, n (%) 16 (64)
Age (years) 65 6 12
Previous antihypertensive medication
Calcium channel blocker, % 60
Diuretics, % 4
BENEFITS OF SWITCHING TO OLMESARTAN 1489Measurement of BP
BP measurements were taken with the patient in the
sitting position using a validated mercury sphygmoma-
nometer. The mean of 2 measurements that provided a
stable value (difference in the values , 5 mm Hg) was
calculated and recorded.
a-Blockers, % 8
ACE inhibitor, % 4
ARBs before enrollment
Candesartan, % 40
Valsartan, % 28
Telmisartan, % 20
Losartan, % 12
Number of antihypertensive drug
1 Drug, % 36
2 Drugs, % 48
3 Drugs, % 16
LDL-C (mg/dL) 102 6 25Statistical Analysis
Analyses were performed with SPSS version 11 soft-
ware (IBM Corporation, Tokyo, Japan). Differences in
the response to olmesartan were assessed with the paired
t test. Measurements are presented as the
mean 6 standard deviation for parametric variables and
as the median (interquartile range) for nonparametric
variables. P values less than .05 were considered statisti-
cally significant.HDL-C (mg/dL) 57 6 10
TG (mg/dL) 219 (141, 252)
FBG (mg/dL) 113 (102, 145)
Hb1Ac (%) 5.8 6 .7
Serum creatinine (mg/dL) .76 6 .20
AST (U/L) 24 6 7
ALT (U/L) 25 6 10
Plasma potassium (mEq/L) 4.4 6 .3
Stroke subtype
Atherothrombotic brain infarction,
n (%)
13 (52)
Cardioembolism, n (%) 1 (4)
Small-vessel occlusion, n (%) 3 (12)
Intracerebral hemorrhage, n (%) 3 (12)
Subarachnoid hemorrhage, n (%) 2 (8)
Others, n (%) 2 (8)
Silent stroke, n (%) 1 (4)
Abbreviations: ACE, angiotensin-converting enzyme; ALT,
alanine transaminase; ARBs, angiotensin II type I receptor blockers;
AST, aspartate transaminase; FBG, fasting blood glucose; HbA1c,
hemoglobin A1c; HDL-C, high-density lipoprotein-C; LDL-C,
low-density lipoprotein-C; TG, triglyceride.
Each datum represents the mean 6 standard deviation.Results
Between July 2009 and December 2012, we screened 26
hypertensive patients who had experienced a stroke or si-
lent cerebral infarct for their eligibility to participate in
this study. During the follow-up period, 1 patient was
dropped because of a change in medications. Conse-
quently, 25 patients were switched to olmesartan and fol-
lowed up for 12 weeks; their baseline characteristics are
shown in Table 1. Their mean age was 65 6 12 years; 16
patients were men, and just over half presented with athe-
rothrombotic brain infarcts. There was no difference in
the baseline characteristics of patients with ischemic
and hemorrhagic stroke. Before entering this study, 16
had taken antihypertensive drugs other than ARBs in
addition to ARBs. They included calcium channel
blockers, diuretics, a-blockers, and ACE inhibitors. The
ARBs administered before enrollment were candesartan,
valsartan, telmisartan, and losartan. The final daily olme-
sartan dose was 10 mg in 3 patients, 20 mg in 18, and
40 mg in 4 patients; the mean dose at follow-up was
22 mg.
Figure 1 shows the level of plasma biomarkers at the
baseline and 12 weeks after the start of olmesartan treat-
ment. To confirm the effects of olmesartan on the level
of Ang-(1-7) and on circulating markers of metabolic syn-
drome, its antioxidative and anti-inflammatory property,
and its proatherogenicity, we measured the level of Ang-
(1-7), adiponectin, peroxiredoxin, HMGB1, TNFa, and the
oxLDL/b2GPI complex. Plasma Ang-(1-7) and adiponec-
tin levels were significantly increased, and the plasma
level of peroxiredoxin and the oxLDL/b2GPI complex
was significantly reduced at 12 weeks after switching to
olmesartan. There was no difference in the plasma
HMGB1 and TNFa levels.
The recommended BP (,140/90 mmHg) was achieved
in 10 patients. Treatment with olmesartan for 12 weeks re-
sulted in a significant reduction in both the systolic anddiastolic BP (Fig 2, A-C). The change in the individual
BP was not necessarily connected with the plasma
biomarkers (data not shown). Olmesartan was well toler-
ated by all patients, and no complications or severe or
fatal adverse events occurred during the 12 weeks of
treatment.Discussion
Our study revealed that switching from other ARBs to
olmesartan significantly increased the plasma level of
Ang-(1-7) and adiponectin and decreased plasma peroxir-
edoxin and the oxLDL/b2GPI complex. Olmesartan
significantly reduced both the systolic and diastolic BP
in patients whose BP had been inadequately controlled
by other ARBs. Our observations suggest that besides
Figure 1. Plasma biomarkers recorded at the inception of the study and 12 weeks after switching to olmesartan. The plasma level of angiotensin-(1-7), adipo-
nectin, peroxiredoxin, HMGB1, TNFa, and oxLDL/b2GPI complex was determined with ELISA. *P , .05: difference between baseline values and the levels
measured at 12 weeks (time comparison). Abbreviations: ELISA, enzyme-linked immunosorbent assay; HMGB1, high mobility group box 1; oxLDL/b2GPI,
oxidized low-density lipoprotein/b-2-glycoprotein I; TNFa, tumor necrosis factor-a.
Y. TADA ET AL.1490its stronger hypotensive effects, olmesartan has greater
beneficial systemic effects than other ARBs.
Schrader et al1 reported that besides lowering the BP,
the administration of ARBs helps to prevent secondary
stroke. The mechanisms underlying the action of ARBs
have been primarily defined on the basis of their specific
blockade of AT1R. Other studies examined the effects of
ARBs on the renin–angiotensin–aldosterone system. Sezai
et al14 found reduced Ang II and aldosterone levels in pa-
tients switched from candesartan to olmesartan. The
administration of telmisartan produced no change in
these levels.18 The drug effects may depend on the type
of ARB delivered even when the ARB blocks AT1R.
Ang-(1-7) exerted effects opposite to those of Ang II; it
yielded organ-protective effects such as reducing cardiac
hypertrophy and fibrosis and decreasing neuronal and
renal damage.
Elsewhere, we demonstrated that olmesartan increased
the mRNA level of ACE2 in the experimental ischemic
brain.3 Igase et al19 showed that it increased the expression
of Ang-(1-7) and ACE2 in the thoracic aorta of spontane-
ously hypertensive rats. Ours is the first study showing
that switching hypertensive patients from other ARBs to
olmesartan increased their plasma level of Ang-(1-7).
Besides their antihypertensive effects, ARBs exert
pleiotropic effects, for example, organ-protective effects.5
Adiponectin, an adipokine produced mainly by adipo-cytes, is thought to be a key protein regulating insulin
resistance and metabolic syndrome.20 Clinical studies
with antihypertensive drugs including ARBs, ACE inhib-
itors, and calcium channel blockers showed a BP reduc-
tion with increased adiponectin levels.21,22 In our
patients, plasma adiponectin was significantly increased
after the switch to olmesartan, suggesting that it has
stronger effects on the adiponectin level than other ARBs.
Peroxiredoxin is one of the most important defenders
against oxidative stress. Its upregulation is associated
with higher levels of oxidative stress, suggesting a sec-
ondary response of peroxiredoxins to oxidative stress.23
The oxLDL/b2GPI complex has been implicated as a
proatherogenic autoantigen.17 In our study, replacing
other ARBs with olmesartan resulted in a reduction in
the level of peroxiredoxin and the oxLDL/b2GPI com-
plex, suggesting that olmesartan has stronger antioxidant
and antiatherogenic properties than other ARBs. Flisher
et al24 demonstrated that inflammatory markers such as
high-sensitivity C-reactive protein, TNFa, interleukin-6,
and monocyte chemotactic protein-1 were decreased in
patients with essential hypertension who were treated
with olmesartan. In our patients, we detected no further
reduction in proinflammatory cytokines including
HMGB1 and TNFa, suggesting that the anti-
inflammatory effects of olmesartan and other ARBs are
comparable.
Figure 2. Systolic blood pressure (SBP) (A)
and diastolic blood pressure (DBP) (B) levels
at the inception of the study and 12 weeks after
switching to olmesartan. Each datum repre-
sents the mean 6 standard deviation.
*P , .05 versus baseline level.
BENEFITS OF SWITCHING TO OLMESARTAN 1491After switching our patients to olmesartan, their cuff
BP readings were lower. As did we, others14,15,25,26
found that olmesartan was superior to other ARBs with
respect to the strength and duration of its
antihypertensive effects. This may be attributable to its
double-chain domain and higher organ affinity.27 In an
experimental study, we found that olmesartan reduced
the plasma aldosterone level in rats (data not shown).
As Ang II and aldosterone are closely involved in BP
elevation, the significant BP reduction we observed in
our patients may be associated with a decrease in the
aldosterone level. Our study did not include patients
treated with azilsartan, a powerful antihypertensive
agent,28 because its use was not approved in Japan at
the inception of this investigation.
Our study has some limitations. We used cuff BP read-
ings although the values obtained by 24-hour ambulatory
BPmonitoringmay be better predictors of stroke, myocar-
dial infarction, and cardiovascular death.29 As the study
population was small and ours was an open-label study,
we cannot exclude the effect(s) of confounding factors.
A large-scale, multicenter, double-blind study will be
needed in the future. Although we had no controls who
continued their ARB treatments, as the duration of those
treatments was 3 months or more before switching to ol-
mesartan, we attribute the observed changes to olmesar-
tan. Because of the small number of patients who had
been treated with other ARBs (candesartan, valsartan, tel-
misartan, and losartan), we analyzed them as a single
group. Lastly, we considered hypertensive patients with
a history of stroke eligible for participation in our studybut we did not confirm that the switch to olmesartan pre-
vented recurrent stroke. Our findings warrant further
studies to assess whether olmesartan prevents recurrent
stroke.
We first document that in patients switched from other
ARBs to olmesartan, the plasma level of Ang-(1-7) and
adiponectin was increased and the level of peroxiredoxin
and the oxLDL/b2GPI complex was decreased. We
demonstrated that olmesartan was more effective than
other ARBs for reducing the BP in patients with a history
of stroke or silent cerebral infarction whose hypertension
was poorly controlled by other ARBs. Our findings sug-
gest that olmesartan may have systemic beneficial effects
beyond its antihypertensive effects and warrant large tri-
als to determine whether olmesartan effectively prevents
stroke recurrence.
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